Abstract
Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
